DE60226175D1 - Mycobakterieller impfstoff - Google Patents

Mycobakterieller impfstoff

Info

Publication number
DE60226175D1
DE60226175D1 DE60226175T DE60226175T DE60226175D1 DE 60226175 D1 DE60226175 D1 DE 60226175D1 DE 60226175 T DE60226175 T DE 60226175T DE 60226175 T DE60226175 T DE 60226175T DE 60226175 D1 DE60226175 D1 DE 60226175D1
Authority
DE
Germany
Prior art keywords
compositions
methods
mycobacterial vaccine
subject
mycobacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226175T
Other languages
English (en)
Other versions
DE60226175T2 (de
Inventor
Craig D Wright
Joan Brisker
Mark A Chambers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of DE60226175D1 publication Critical patent/DE60226175D1/de
Application granted granted Critical
Publication of DE60226175T2 publication Critical patent/DE60226175T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE60226175T 2001-11-14 2002-11-13 Mycobakterieller impfstoff Expired - Lifetime DE60226175T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33591701P 2001-11-14 2001-11-14
US335917P 2001-11-14
PCT/US2002/036336 WO2003051288A2 (en) 2001-11-14 2002-11-13 Mycobacterial vaccine

Publications (2)

Publication Number Publication Date
DE60226175D1 true DE60226175D1 (de) 2008-05-29
DE60226175T2 DE60226175T2 (de) 2009-07-09

Family

ID=23313769

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226175T Expired - Lifetime DE60226175T2 (de) 2001-11-14 2002-11-13 Mycobakterieller impfstoff

Country Status (10)

Country Link
US (1) US7393541B2 (de)
EP (1) EP1467771B1 (de)
JP (1) JP2005538923A (de)
KR (1) KR20040081423A (de)
CN (1) CN1612753A (de)
AT (1) ATE392216T1 (de)
AU (1) AU2002364952B2 (de)
CA (1) CA2467271A1 (de)
DE (1) DE60226175T2 (de)
WO (1) WO2003051288A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364952B2 (en) * 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
CU23460A1 (es) * 2004-03-18 2009-12-01 Inst Finlay Ct De Investigacio Composiciones vacunales obtenidas a partir de streptomyces
WO2006071659A1 (en) * 2004-12-29 2006-07-06 Trustees Of Boston University Delivery of h2 antagonists
CN100999550B (zh) 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
EP2111232A4 (de) * 2006-07-06 2010-09-08 Rajesh Shah Neue medizinische formulierung zur auslösung einer immunantwort bei patienten mit chronischen und wiederkehrenden infektionen
US8394389B2 (en) * 2007-04-12 2013-03-12 Mico Bio, Inc. Tuberculosis vaccine and method of using same
CN102858367B (zh) * 2010-02-26 2014-12-17 国立大学法人长崎大学 抗原或药物递送复合物
RU2612788C2 (ru) 2010-03-23 2017-03-13 Интрексон Корпорейшн Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
CN110075287A (zh) 2013-03-15 2019-08-02 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
KR101696514B1 (ko) * 2014-08-18 2017-01-24 서울대학교산학협력단 신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
US11077179B2 (en) * 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474848A (en) * 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
BR9506885A (pt) * 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
AU2001245823A1 (en) * 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002364952B2 (en) * 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2005538923A (ja) 2005-12-22
KR20040081423A (ko) 2004-09-21
EP1467771A4 (de) 2006-01-11
CA2467271A1 (en) 2003-06-26
EP1467771A2 (de) 2004-10-20
WO2003051288A3 (en) 2003-11-27
WO2003051288A2 (en) 2003-06-26
ATE392216T1 (de) 2008-05-15
EP1467771B1 (de) 2008-04-16
US7393541B2 (en) 2008-07-01
US20050118201A1 (en) 2005-06-02
DE60226175T2 (de) 2009-07-09
AU2002364952A1 (en) 2003-06-30
CN1612753A (zh) 2005-05-04
AU2002364952B2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
ATE392216T1 (de) Mycobakterieller impfstoff
ATE426412T1 (de) Adjuvante influenza-vakzine
DK1401489T4 (da) Solubilisering af kapselpolysaccharid
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
WO2003080114A3 (en) Imidazoquinoline adjuvants for vaccines
CY1115842T1 (el) Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου
CY1106669T1 (el) Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
CY1108526T1 (el) Εμβολια εναντι καρκινων
WO2002010343A3 (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
ATE543511T1 (de) Attenuierte lebendimpfstoffe gegen pleuropneumonie bei schweinen
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
WO2006095176A3 (en) Vaccine formulation
CY1114309T1 (el) Εμβολιο ροταϊου
UA67251A (en) Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums

Legal Events

Date Code Title Description
8364 No opposition during term of opposition